AR057977A1 - Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. composiciones farmaceuticas. - Google Patents

Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. composiciones farmaceuticas.

Info

Publication number
AR057977A1
AR057977A1 ARP060103784A ARP060103784A AR057977A1 AR 057977 A1 AR057977 A1 AR 057977A1 AR P060103784 A ARP060103784 A AR P060103784A AR P060103784 A ARP060103784 A AR P060103784A AR 057977 A1 AR057977 A1 AR 057977A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halogen
group
hydrogen
Prior art date
Application number
ARP060103784A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057977A1 publication Critical patent/AR057977A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composiciones farmacéuticas que contienen dichos compuestos, y uso de los mismos para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de los receptores de SST del subtipo 5. Reivindicacion 1: Compuestos de la formula general (1), en la que X es S u O; A es CR3 y B es CR4, o A es N o N+-O- y B es CR4 o B es N o N+-O- y A es CR3; R1 y R2 con independencia entre sí se eligen entre el grupo formado por hidrogeno, halogeno, ciano, nitro, alquilo C1-7, hidroxi-alquilo C1-7, alcoxi C1-7-alquilo C1-7-alcoxi C1-7, hidroxi-alcoxi C2-7, dihidroxi-alcoxi C3-7, carboxi-alcoxi C1-7, (alcoxi C1-7)-carbonil-alcoxi C1-7, carboxi-alquilo C1-7, (alcoxi C1-7)-carbonil-alquilo C1-7, 1H-tetrazol-5-il-alcoxi C1-7, piridinil- alcoxi C1-7, -NR5R6, -NHCOR7, -NHSO2R8, -SO2NR9R10, 1H-tetrazoI-5-ilo, fenilo sin sustituir y fenilo sustituido de una a tres veces por sustituyentes elegidos entre alquilo C1-7, cicloalquilo C3-7, halogeno, halogeno-alquilo C1-7 y alcoxi C1-7 y R2 puede elegirse además entre el grupo formado por carboxi, alcoxi C1-7-carbonilo y -CONR11R12; R5 y R6 con independencia entre sí se eligen entre el grupo formado por hidrogeno, alquilo C1-7, hidroxi-alquilo C1-7 y cicloalquilo C3-7; R7 se elige entre el grupo formado por alquilo C1-7, cicloalquilo C3-7, halogeno-alquilo C1-7, hidroxi-alquilo C1-7, alcoxi C1-7-alquilo C1-7, carboxi-alquilo C1-7, (alcoxi C1-7)-carbonil-alquilo C1-7, 1H-tetrazol-5-il-alquilo C1-7, fenilo sin sustituir, fenilo sustituido de una a tres veces por restos elegidos entre el grupo formado por alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo C1-7 y halogeno; heteroarilo sin sustituir, heteroarilo sustituido por uno o dos restos elegidos entre alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo C1-7 o halogeno; heteroaril-alquilo C1-7 sin sustituir y heteroaril-alquilo C1-7, en el que el heteroarilo está sustituido por uno o dos grupos elegidos entre alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo C1-7 y halogeno; R8 se elige entre el grupo formado por alquilo C1-7, cicloalquilo C3-7, heteroarilo sin sustituir y heteroarilo sustituido por uno o dos restos elegidos entre alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo C1-7 y halogeno; R9 y R10 con independencia entre sí se eligen entre el grupo formado por hidrogeno, alquilo C1-7, cicloalquilo C3-7, heteroarilo sin sustituir y heteroarilo sustituido por uno o dos restos elegidos entre alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo C1-7 y halogeno; o R9 y R10 junto con el átomo de nitrogeno al que están unidos forman un anillo de pirrolidina o de piperidina; R11 se elige entre el grupo formado por hidrogeno, alquilo C1-7 y cicloalquilo C3-7; R12 se elige entre el grupo formado por hidrogeno, alquilo C1-7, cicloalquilo C3-7, halogeno-alquilo C1-7, hidroxi-alquilo C1-7, alcoxi C1-7-alquilo C1-7, carboxialquilo C1-7, (alcoxi C1-7)-carbonil-alquilo C1-7, fenilo sin sustituir, fenilo sustituido de una a tres veces por restos elegidos entre el grupo formado por alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo C1-7 y halogeno; heteroarilo sin sustituir, heteroarilo sustituido por uno o dos restos elegidos entre alquilo C1-7, cicloalquilo C3-7, alcoxi C1-7, halogeno-alquilo y halogeno; uno de R3 y R4 se elige entre el grupo formado por hidrogeno, alquilo C1-7, nitro y alcoxi C1-7 o está ausente en el caso de que uno de A o B sea N o N+-O-, y el otro de R3 y R4 se elige entre el grupo formado por hidrogeno, alquilo C1-7, alcoxi C1-7, hidroxi, hidroxi-alquilo C1-7, ciano-alcoxi C1-7, cicloalquiloxi C3-7, donde el grupo cicloalquilo está sustituido por carboxi o alcoxi C1-7- carbonilo; carboxi, alcoxi C1-7-carbonilo, carboxi-alcoxi C1-7, (alcoxi C1-7)-carbonil-alquilo C1-7, carboxi-alquilo C1-7, (alcoxi C1-7)-carbonil-alcoxi C1-7, 1H-tetrazol-5-il-alcoxi C1-7, triazolil-alcoxi C1-7, alquilsulfoniloxi C1-7, alquilsulfoniloxi C1-7-alcoxi C1-7, hidroxi-alcoxi C2-7, dihidroxi-alcoxi C3-7, alcoxi C1-7-alcoxi C1-7, -(CH2)n-N R13R14, -(CH2)n-NHCOR15, amino-alcoxi C1-7, aminocarbonil-alcoxi C1-7, alquil C1-7-aminocarbonil-alcoxi C1-7 y 1H-tetrazol-5-ilo; R13 y R14 con independencia entre sí se eligen entre el grupo formado por hidrogeno, alquilo C1-7 y cicloalquilo C3-7; R15 se elige entre el grupo formado por alquilo C1-7, cicloalquilo C3-7, halogeno-alquilo C1-7, hidroxi-alquilo C1-7, alcoxi C1-7- alquilo C1-7, carboxi-alquilo C1-7 y (alcoxi C1-7)-carbonil-alquilo C1-7; n es un numero entero elegido entre 1, 2 y 3; con la condicion de que se excluyan los benzooxazoles y benzotiazoles en los que R1, R2, R3 y R4 son hidrogeno; G se elige entre los restos G1 a G5, en los que R16 es hidrogeno o halogeno; R17 se elige entre el grupo formado por alcoxi C1-7, alqueniloxi C2-7, cicloalquiloxi C3-7, -NR29R30, halogeno-alcoxi C1-7, alcoxi C1-7-alcoxi C1-7 y alcoxi C1-7-alquilo C1-7; R29 y R30 con independencia entre sí son hidrogeno o alquilo C1-7; R18 se elige entre el grupo formado por hidrogeno, alquilo C1-7, halogeno-alquilo C1-7, hidroxi, alcoxi C1-7, halogeno-alcoxi C1-7, cicloalquiloxi C3-7, halogeno, pirrolilo, imidazolilo, triazolilo, -CO2R31, -NR32R33, -SOR34; fenilo sin sustituir y fenilo sustituido por uno o dos restos elegidos entre el grupo formado por alquilo C1-7, halogeno-alquilo C1-7, halogeno-alcoxi C1-7, alcoxi C1-7 y halogeno; R31 es hidrogeno o alquilo C1- 7; R32 y R33 con independencia entre sí son hidrogeno o alquilo C1-7; R34 es alquilo C1-7; R19 se elige entre el grupo formado por hidrogeno, alquilo C1-7, halogeno, alcoxi C1-7, alqueniloxi C2-7, -O-tetrahidropiranilo, cicloalquiloxi C3-7, halogenoalcoxi C1-7, alcoxi C1-7-alcoxi C1-7 y alcoxi C1-7-alquilo C1-7; R20 es hidrogeno o halogeno; R21 es hidrogeno o alquilo C1-7; R22 y R23 con independencia entre sí se eligen entre el grupo formado por hidrogeno, alquilo C1-7, alcoxi C1-7 y nitro; R24 es fenilo sin sustituir o fenilo sustituido por uno o dos restos elegidos entre el grupo formado por alquilo C1-7, alcoxi C1-7 y halogeno; R25 es alcoxi C1-7; R26 y R27 con independencia entre sí son alquilo C1-7; R28 es alcoxi C1-7; y las sales farmacéuticamente aceptables de los mismos.
ARP060103784A 2005-09-02 2006-08-30 Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. composiciones farmaceuticas. AR057977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108035 2005-09-02

Publications (1)

Publication Number Publication Date
AR057977A1 true AR057977A1 (es) 2008-01-09

Family

ID=37527780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103784A AR057977A1 (es) 2005-09-02 2006-08-30 Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. composiciones farmaceuticas.

Country Status (15)

Country Link
US (2) US20070093521A1 (es)
EP (1) EP1924579B1 (es)
JP (1) JP4855468B2 (es)
KR (1) KR101047221B1 (es)
CN (1) CN101253171B (es)
AR (1) AR057977A1 (es)
AT (1) ATE497959T1 (es)
AU (1) AU2006286573B2 (es)
BR (1) BRPI0615449A2 (es)
CA (1) CA2620127A1 (es)
DE (1) DE602006020049D1 (es)
ES (1) ES2359431T3 (es)
IL (1) IL189664A (es)
TW (1) TW200740827A (es)
WO (1) WO2007025897A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060168066A1 (en) * 2004-11-10 2006-07-27 David Helsper Email anti-phishing inspector
AU2006222243B2 (en) * 2005-03-09 2012-04-05 F. Hoffmann La-Roche Ag Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds
EP1900729A1 (en) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
CA2743489A1 (en) * 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2011031628A1 (en) * 2009-09-14 2011-03-17 Schering Corporation Inhibitors of diacylglycerol acyltransferase
TW201114762A (en) * 2009-09-30 2011-05-01 Sumitomo Chemical Co Composition and method for controlling arthropod pests
US8481547B2 (en) 2009-12-18 2013-07-09 Janssen Pharmaceutica Nv Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
US20130040978A1 (en) * 2010-05-18 2013-02-14 Joseph L. Duffy Spiro isoxazoline compounds as sstr5 antagonists
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
CA2989098A1 (en) 2015-06-22 2016-12-29 Actelion Pharmaceuticals Ltd Nadph oxidase 4 inhibitors
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469697A (en) * 1946-12-05 1949-05-10 Eastman Kodak Co Preparation of 2-chlorobenzothiazole
US4861785A (en) * 1984-12-03 1989-08-29 Janssen Pharmaceutica N.V. Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents
CA1260474A (en) * 1984-12-03 1989-09-26 Raymond A. Stokbroekx Benzoxazol- and benzothiazolamine derivatives
FR2766822B1 (fr) * 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE375333T1 (de) * 2002-08-07 2007-10-15 Neuraxon Inc Aminobenzothiazolverbindungen mit nos-hemmender wirkung
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
UA82888C2 (en) * 2003-07-28 2008-05-26 Janssen Pharmaceutica Nv Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
AU2006222243B2 (en) * 2005-03-09 2012-04-05 F. Hoffmann La-Roche Ag Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds

Also Published As

Publication number Publication date
JP2009506996A (ja) 2009-02-19
WO2007025897A3 (en) 2007-05-10
US20070093521A1 (en) 2007-04-26
AU2006286573B2 (en) 2012-05-31
CN101253171B (zh) 2011-06-15
DE602006020049D1 (de) 2011-03-24
KR101047221B1 (ko) 2011-07-06
ES2359431T3 (es) 2011-05-23
TW200740827A (en) 2007-11-01
IL189664A (en) 2011-12-29
EP1924579A2 (en) 2008-05-28
KR20080043380A (ko) 2008-05-16
CN101253171A (zh) 2008-08-27
EP1924579B1 (en) 2011-02-09
ATE497959T1 (de) 2011-02-15
BRPI0615449A2 (pt) 2011-05-17
US20090163517A1 (en) 2009-06-25
IL189664A0 (en) 2008-06-05
CA2620127A1 (en) 2007-03-08
WO2007025897A2 (en) 2007-03-08
AU2006286573A1 (en) 2007-03-08
JP4855468B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
AR057977A1 (es) Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. composiciones farmaceuticas.
AR043049A1 (es) Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica
AR062357A1 (es) Derivados de fenilo, piridina y quinolina, composiciones farmaceuticas y su utilizacion como medicamentos
AR052588A1 (es) Derivados de benzotiazol tiazolopiridina benzooxazol y oxazolopiridina
AR053352A1 (es) Heterociclos sustituidos y sus usos como inhibidores de quinasas
AR037754A1 (es) Herbicidas
AR062928A1 (es) Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
AR082681A1 (es) Inhibidores del virus de la hepatitis c
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
AR055830A1 (es) Inhibidores de cxcr2
AR051469A1 (es) Derivados de indol tetraciclicos como agentes antiviricos
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
CO5300399A1 (es) Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR051393A1 (es) Adeninas sustituidas y sus usos
UY30387A1 (es) Nuevos compuestos
CR10027A (es) Nuevos derivados de pirrol fusionado
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR055617A1 (es) Derivados de benzotiazolona, composiciones farmaceuticas que los contienen, proceso de preparacion y usos como agonistas de adrenoreceptores beta2
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR049433A1 (es) Derivados de naftalina
AR061515A1 (es) Benzoxazoles sustituidos con heteroarilo. composiciones farmaceuticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal